Pediatric Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine (Monovalent and Multivalent), By Indication (Pneumococcal Conjugate Vaccine, DTP Vaccine, Influenza, Meningococcal Vaccine, Polio Vaccine, Rotavirus Vaccine, MMR Vaccine, and Varicella Virus Vaccine), By Technology (Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, and Recombinant Vector Vaccine), and Region Forecast 2019-2030

Purchase Option

$ 4400
$ 6600
$ 8900

Pediatric Vaccine Market size was valued at USD 23,749.8 million in 2023 and is expected to grow at a CAGR of 9.8% over the forecast year to reach USD 45,695.8 million in 2030. Vaccines for children are administered to guard against serious and frequently fatal infections. It primes the body to combat the illness more quickly and successfully by boosting the body. Globally increasing awareness of vaccinations and immunization initiatives will propel the pediatric vaccine industry.

Moreover, opportunities are surfacing in vaccine technology, including mRNA vaccines, and also through the increasing requirements for combination vaccines to reduce the number of injections required. Significant restrictions to the pediatric vaccine market include the presence of vaccine hesitation, where parents and caregivers refuse to vaccinate their children because of safety concerns or unsubstantiated myths. Furthermore, coverage in low-income or rural regions is at a disadvantage as the availability of healthcare infrastructure differs across different areas. The cost of developing and manufacturing vaccines may also become a formidable challenge, particularly for smaller manufacturers.

This being the third reason why the vaccination rate of children is suboptimal, it's because of the regulatory hurdles and the long time taken to have approval for a new vaccine. Thus, these elements have contributed to the challenges of achieving high vaccination rates among children. These are the trends that emerging in the market by a phenomenon where the public and private sectors have been joining forces to increase vaccination coverage. Reports recently indicate that the global market for pediatric vaccines will be about $40 billion in 2027 with a CAGR of around 7% in comparison, showing a continuation of the efforts to advance child health through immunization.

Pediatric Vaccine Market Key Developments

  • In March 2024, The European Commission approved the Pfizer PREVENAR 20 vaccine, which provides the widest serotype coverage for the prevention of pneumococcal disease in children. The vaccine was approved based on significant Phase 3 trial data demonstrating safety and effectiveness, like others in its class that have recently received approval in the U.S., Canada, Australia, and elsewhere.
  • In November 2022, Indian Immunologicals Limited, in pursuance of its new vaccines, launched Mabella, a measles and rubella vaccine in the market for children. It was developed in collaboration with the Polyvac Institute of Vietnam as a live-attenuated vaccine, which has proven to be safe and effective in clinical trials. Launched to commemorate the silver jubilee year of IIL's Human Biologicals Institute established 25 years ago underlines the significant contributions of the company towards developing vaccines and disease management in India.

Pediatric Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Pediatric Vaccine Market Dynamics

 The pediatric vaccine market is steadily growing with various opportunities it includes inventing mRNA vaccines and developing new vaccine technology to open avenues for more effective immunization against a wide series of diseases. For instance, with a global CAGR of almost 8% during 2023-2028 where parents opt for fewer injections in children, the combination vaccines market can be expanded. Additionally, public health campaigns increase awareness of the importance of vaccinations. Therefore, the demand for pediatric vaccines increases. It's also reported that immunization programs are expanding globally, especially in developing countries, because global health organizations are providing support to enhance vaccine accessibility and coverage. Overall, pediatric vaccines have a promising future in growth as healthcare systems continue to improve the health of children through new inventions and global efforts toward immunization.

Pediatric Vaccine Market Segmentation

By Vaccine

  • Monovalent
  • Multivalent

By Indication

  • Pneumococcal Conjugate Vaccine
  • DTP Vaccine
  • Influenza
  • Meningococcal Vaccine
  • Polio Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Varicella Virus Vaccine

By Technology

  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vector Vaccine

Frequently Asked Questions

The pediatric vaccine market was valued at USD 23,749.8 million in 2023 and is expected to grow at a CAGR of 9.8% over the forecast year to reach USD 45,695.8 million in 2030.

The pediatric vaccine market is growing due to increased awareness of vaccines and their immunization programs across the globe.

The pediatric vaccine market is emerging with this trend it includes public and private sectors have been joining forces to increase vaccination coverage.

North America is the dominant region in the pediatric vaccine market.

Asai-Pacific is the fastest-growing region in the pediatric vaccine market.

Key Features of the Report

  • The pediatric vaccine market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Pediatric Vaccine Market Introduction 
2.1.Global Pediatric Vaccine Market  - Taxonomy
2.2.Global Pediatric Vaccine Market  - Definitions
2.2.1.Vaccine
2.2.2.Indication
2.2.3.Technology
2.2.4.Region
3.Global Pediatric Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Pediatric Vaccine Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Pediatric Vaccine Market  By Vaccine, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Monovalent
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Multivalent
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Pediatric Vaccine Market  By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Pneumococcal Conjugate Vaccine
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. DTP Vaccine
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Influenza
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Meningococcal Vaccine
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Polio Vaccine
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Rotavirus Vaccine
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. MMR Vaccine
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Varicella Virus Vaccine
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
7.Global Pediatric Vaccine Market  By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Live or Attenuated Vaccine
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Inactivated or Killed Vaccine
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Toxoid Vaccine
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Conjugate Vaccine
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Subunit Vaccine
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
7.6. Recombinant Vector Vaccine
7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.6.3. Market Opportunity Analysis 
8.Global Pediatric Vaccine Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Vaccine Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Monovalent
9.1.2.Multivalent
9.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Pneumococcal Conjugate Vaccine
9.2.2.DTP Vaccine
9.2.3.Influenza
9.2.4.Meningococcal Vaccine
9.2.5.Polio Vaccine
9.2.6.Rotavirus Vaccine
9.2.7.MMR Vaccine
9.2.8.Varicella Virus Vaccine
9.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Live or Attenuated Vaccine
9.3.2.Inactivated or Killed Vaccine
9.3.3.Toxoid Vaccine
9.3.4.Conjugate Vaccine
9.3.5.Subunit Vaccine
9.3.6.Recombinant Vector Vaccine
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Vaccine Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Monovalent
10.1.2.Multivalent
10.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Pneumococcal Conjugate Vaccine
10.2.2.DTP Vaccine
10.2.3.Influenza
10.2.4.Meningococcal Vaccine
10.2.5.Polio Vaccine
10.2.6.Rotavirus Vaccine
10.2.7.MMR Vaccine
10.2.8.Varicella Virus Vaccine
10.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Live or Attenuated Vaccine
10.3.2.Inactivated or Killed Vaccine
10.3.3.Toxoid Vaccine
10.3.4.Conjugate Vaccine
10.3.5.Subunit Vaccine
10.3.6.Recombinant Vector Vaccine
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Vaccine Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Monovalent
11.1.2.Multivalent
11.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Pneumococcal Conjugate Vaccine
11.2.2.DTP Vaccine
11.2.3.Influenza
11.2.4.Meningococcal Vaccine
11.2.5.Polio Vaccine
11.2.6.Rotavirus Vaccine
11.2.7.MMR Vaccine
11.2.8.Varicella Virus Vaccine
11.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Live or Attenuated Vaccine
11.3.2.Inactivated or Killed Vaccine
11.3.3.Toxoid Vaccine
11.3.4.Conjugate Vaccine
11.3.5.Subunit Vaccine
11.3.6.Recombinant Vector Vaccine
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Vaccine Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Monovalent
12.1.2.Multivalent
12.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Pneumococcal Conjugate Vaccine
12.2.2.DTP Vaccine
12.2.3.Influenza
12.2.4.Meningococcal Vaccine
12.2.5.Polio Vaccine
12.2.6.Rotavirus Vaccine
12.2.7.MMR Vaccine
12.2.8.Varicella Virus Vaccine
12.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Live or Attenuated Vaccine
12.3.2.Inactivated or Killed Vaccine
12.3.3.Toxoid Vaccine
12.3.4.Conjugate Vaccine
12.3.5.Subunit Vaccine
12.3.6.Recombinant Vector Vaccine
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Vaccine Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Monovalent
13.1.2.Multivalent
13.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Pneumococcal Conjugate Vaccine
13.2.2.DTP Vaccine
13.2.3.Influenza
13.2.4.Meningococcal Vaccine
13.2.5.Polio Vaccine
13.2.6.Rotavirus Vaccine
13.2.7.MMR Vaccine
13.2.8.Varicella Virus Vaccine
13.3.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Live or Attenuated Vaccine
13.3.2.Inactivated or Killed Vaccine
13.3.3.Toxoid Vaccine
13.3.4.Conjugate Vaccine
13.3.5.Subunit Vaccine
13.3.6.Recombinant Vector Vaccine
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Sanofi
14.2.2.AstraZeneca
14.2.3.GSK plc 
14.2.4.Pfizer, Inc.
14.2.5.Zydus Group
14.2.6.Serum Institute of India Pvt. Ltd.
14.2.7.Indian Immunologicals Ltd.
14.2.8.SINOVAC 
14.2.9.Panacea Biotec 
14.2.10.BIO-MED
15. Research Methodology 
16. Appendix and Abbreviations 
  • Sanofi
  • AstraZeneca
  • GSK plc 
  • Pfizer, Inc.
  • Zydus Group
  • Serum Institute of India Pvt. Ltd.
  • Indian Immunologicals Ltd.
  • SINOVAC 
  • Panacea Biotec 
  • BIO-MED

Adjacent Markets